Sidra Medicine to introduce CAR T-cell therapy for paediatric cancer in Qatar

Doha: In a major development for childhood cancer treatment, an internationally approved treatment method will be introduced soon in Qatar. Sidra M...

Doha: In a major development for childhood cancer treatment, an internationally approved treatment method will be introduced soon in Qatar.

Sidra Medicine, a leading institution in cutting-edge medical research and treatment, is validating CAR T-cell therapy at its state-of-the-art Good Manufacturing Practice (GMP) facility.

Director of the Advanced Cell Therapy Core and the GMP Facility at Sidra Medicine, Dr. Chiara Cugno announced that this innovative approach is set to bring new hope to paediatric patients with leukaemia in Qatar. “We opened the GMP facility only few months ago, and currently we are validating the procedure for the CAR-T manufacturing,” said Dr. Cugno while speaking to The Peninsula on the sidelines of the fourth edition of the Science Cafe series titled: ‘Hope for Little Heroes: Revolutionizing Pediatric Cancer Therapies,’ on Monday.

Organised by Msheireb Museums and Sidra Medicine, the event focused on advancement and several key topics about the future of precision medicine in childhood cancer care in Qatar.

CAR T-cell therapy is a type of treatment for cancer that uses a person’s own immune cells to fight cancer. Validation of CAR-T cell therapy involves proving through rigorous testing that it works well and is safe for treating cancer.